| __timestamp | Eli Lilly and Company | Travere Therapeutics, Inc. |
|---|---|---|
| Wednesday, January 1, 2014 | 6620800000 | 59644696 |
| Thursday, January 1, 2015 | 6533000000 | 79541000 |
| Friday, January 1, 2016 | 6452000000 | 98015000 |
| Sunday, January 1, 2017 | 6588100000 | 103958000 |
| Monday, January 1, 2018 | 5975100000 | 103654000 |
| Tuesday, January 1, 2019 | 6213800000 | 128951000 |
| Wednesday, January 1, 2020 | 6121200000 | 135799000 |
| Friday, January 1, 2021 | 6431600000 | 149883000 |
| Saturday, January 1, 2022 | 6440400000 | 220206000 |
| Sunday, January 1, 2023 | 6941200000 | 265542000 |
| Monday, January 1, 2024 | 8593800000 |
Unleashing the power of data
In the competitive landscape of pharmaceuticals, understanding spending patterns is crucial. Eli Lilly and Company, a stalwart in the industry, has consistently allocated significant resources to Selling, General, and Administrative (SG&A) expenses. From 2014 to 2023, Eli Lilly's SG&A expenses have shown a steady increase, peaking in 2023 with a 5% rise from the previous year. This reflects their strategic focus on maintaining market leadership and innovation.
Conversely, Travere Therapeutics, Inc., a smaller player, has demonstrated a more dynamic growth in SG&A spending. Over the same period, Travere's expenses surged by over 340%, highlighting their aggressive expansion and market penetration strategies. This stark contrast in spending patterns underscores the diverse approaches companies take to thrive in the pharmaceutical sector.
These insights offer a glimpse into how financial strategies can shape the future of pharmaceutical giants and emerging contenders alike.
Selling, General, and Administrative Costs: Eli Lilly and Company vs Pharming Group N.V.
Operational Costs Compared: SG&A Analysis of Eli Lilly and Company and Axsome Therapeutics, Inc.
Comparing SG&A Expenses: Eli Lilly and Company vs Merus N.V. Trends and Insights
SG&A Efficiency Analysis: Comparing Eli Lilly and Company and Vericel Corporation
SG&A Efficiency Analysis: Comparing Summit Therapeutics Inc. and Travere Therapeutics, Inc.
Blueprint Medicines Corporation and Travere Therapeutics, Inc.: SG&A Spending Patterns Compared
SG&A Efficiency Analysis: Comparing Corcept Therapeutics Incorporated and Travere Therapeutics, Inc.
Cost Management Insights: SG&A Expenses for Ionis Pharmaceuticals, Inc. and Travere Therapeutics, Inc.
Selling, General, and Administrative Costs: Verona Pharma plc vs Travere Therapeutics, Inc.
SG&A Efficiency Analysis: Comparing Mesoblast Limited and Travere Therapeutics, Inc.
Breaking Down SG&A Expenses: MannKind Corporation vs Travere Therapeutics, Inc.
SG&A Efficiency Analysis: Comparing Amphastar Pharmaceuticals, Inc. and Travere Therapeutics, Inc.